Skip to main content

Animations

MJFF Publications

8551 - 8560 of 8808 Results
Title
Year
  • Year
  • 2016
  • 2023
  • 2024
  • 2024
  • 2020
  • 2018
  • 2019
  • 2025
  • 2025
  • 2018
  • Summary Details
    RESTRICTED
    Title: Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26483
    Citation Count: 41
  • Summary Details
    OPEN
    Title: Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1021/acschemneuro.3c00259
    Citation Count: 17
  • Summary Details
    OPEN
    Title: The ZFHX3 GGC Repeat Expansion Underlying Spinocerebellar Ataxia Type 4 has a Common Ancestral Founder
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.30077
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome‐Wide Association Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.30054
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.94.15_supplement.2490
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease
    Journal Name: Molecular Neurobiology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s12035-018-1109-6
    Citation Count: 56
  • Summary Details
    OPEN
    Title: The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss
    Journal Name: Experimental Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.expneurol.2019.05.002
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Relationships between neuropsychiatric symptoms, subtypes of astrocyte activities, and brain pathologies in Alzheimer's disease and Parkinson's disease
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/alz.70242
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Genome-wide association study of REM sleep behavior disorder in Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-025-01078-w
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Nicotinamide-N-methyltransferase controls behavior, neurodegeneration and lifespan by regulating neuronal autophagy
    Journal Name: PLOS Genetics
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pgen.1007561
    Citation Count: 39
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.